Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | AGER | Q15109 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503977 | 0.86 | GAA (0.65) | GAASMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL4654289 | 0.84 | GAA (0.63) | GAASMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL7293033 | 0.80 | GAA (0.58) | GAASMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL7646661 | 0.79 | HPGD (0.50) | GAASMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL8581819 | 0.79 | HPGD (0.62) | GAASMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL11013166 | 0.78 | GAA (0.52) | GAASMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL11013164 | 0.78 | GAA (0.52) | GAASMN1; SMN2NPC1RAB9AL3MBTL1 | |
| Isopeonol SCHEMBL1376231 | 0.76 | MAOB (0.57) | GAASMN1; SMN2NPC1RAB9AMAPK1 | |
| Peonol Methyl Ether SCHEMBL246262 | 0.76 | ALDH1A1 (0.67) | GAASMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL20630742 | 0.76 | KMT2A (0.57) | SMN1; SMN2NPC1RAB9AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271634-B1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2014-02-12 | — | — | EP | disclosed |
| US-8524766-B2 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-09-03 | — | — | US | disclosed |
| US-8492372-B2 | Modulators of dopamine neurotransmission | INTEGRATED RESEARCH LABORATORIES SWEDEN AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| EP-2271638-B1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2011-08-31 | — | — | EP | disclosed |
| US-20110112065-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-12 | — | — | US | disclosed |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
| EP-2271634-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-01-12 | — | — | EP | disclosed |
| EP-2271638-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-01-12 | — | — | EP | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009133107-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009133110-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2009-11-05 | — | — | WO | disclosed |
| EP-1644334-B1 | ANTITHROMBOTIC ETHERS | LILLY CO ELI (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6479520-B1 | REGULATING APOPTOSIS IN HUMAN CELLS WITH COMPOUNDS SUCH AS: 3-CYANO-6-(2-METHOXY-4-METHYLTHIOIPHENYL)-2(1H)-PYRIDINONE | CELL PATHWAYS, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6046216-A | USEFUL TO INHIBIT THE GROWTH OF NEOPLASTIC CELLS. | CELL PATHWAYS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112065-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | SLC18A2, SYNGR2, DBH | GAA 2807/4885SMN1; SMN2 622/4885NPC1 2321/4885 |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | GAA 2224/4885SMN1; SMN2 689/4885NPC1 1846/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | GAA 3750/4885SMN1; SMN2 3014/4885NPC1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.